Merck's Diabetic Retinopathy Treatment Shows Promising Trial Results

Merck's experimental treatment for diabetic retinopathy has shown promise in clinical trials. The company's drug, which targets the underlying causes of vision loss associated with diabetes, demonstrated a statistically significant reduction in the rate of severe visual impairment.

The trial results, which were presented at an industry conference, showed that patients receiving the treatment experienced a 45% lower risk of severe visual impairment compared to those on a placebo. The researchers noted that this was a key metric because it is directly related to the patient's quality of life and independence.

Diabetic retinopathy affects millions worldwide, with the majority living in low- and middle-income countries. Current treatments often focus on managing symptoms rather than addressing the underlying causes of vision loss.